Hot News

長科飆1成 擬拆癌症治療業務於美上市 @ 2012-08-13T11: Back Hot News
Keyword:業務
Concept:長科擬分拆治癌業務美上市 , 分拆癌症免疫治療方案研發業務POLYNOMA
長江生命(00775)擬分拆癌症免疫治療方案研發業務 升逾一成
長江生命科技(775)已就分拆癌症免疫治療方案的研發業務,於美國納斯特證券市場上市,向聯交所遞交建議,完成分拆...
核數師提請垂注,3月止集團及公司之流動負債淨額分別為2.28億元及1.6億元,條件顯示存在重大不明朗因素,可能對持續經營能力構成重大疑問。 交通銀行宣布,獲中證監核准非公開發行不超過65.42億股新A股及58.35億股新H股。 長江生命科技公布,基於建議分拆癌症免疫治療方案的研發業務POLYNOMA股份擬於美國納斯達克證券市場招股,公司正就此考慮連串有關將所持POLYNOMA股權重組之交易,以使新公司成為POLYNOMA之控股公司。分拆完成後,長江生科持有新公司股本約49.3%-58.5%。
長科擬分拆癌症免疫治療方案研發業務

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.